70 - Clinical Metagenomics: Current State & Opportunities

Thursday, October 17, 2024

1:45 PM – 3:00 PM US PT

Location: 515 B

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Patricia Simner, PhD

Associate Professor, Director of Bacteriology
Johns Hopkins School of Medicine
Baltimore, MD, United States
Senu Apewokin, MD

Assoc Prof
University of Cincinnati
Mason, OH, United States

Faculty(s)

Etienne Ruppe, PharmD, PhD (he/him/his)

Full professor
Université Paris Cité
Catherine Hogan, MD, MSc

Clinical Assistant Professor, University of British Columbia
British Columbia Centre for Disease Control
North Vancouver, BC, Canada
David Gaston, MD PhD

Assistant Professor, Medical Director (Molecular Infectious Disease Laboratory)
Vanderbilt University Medical Center
Nashville, TN, United States

Disclosure(s):

Patricia J. Simner, PhD: Affinity Biosensors: Grant/Research Support; BD Diagnostics: Grant/Research Support; bioMérieux: Grant/Research Support; Entasis: Personal fees; GeneCapture: Personal Fees; Merck: Personal fees; OpGen Inc: Grant/Research Support; Qiagen: Grant/Research Support; Shionogi: Personal fees; T2 Biosystems: Grant/Research Support

Senu Apewokin, MD: Nestle/Seres: Stocks/Bonds (Public Company) (Terminated, June 30, 2023); Speakers Bureau for Nestle Health Science: Honoraria (Ongoing)

Etienne Ruppe, PharmD, PhD: No financial relationships to disclose

Catherine Hogan, MD, MSc: Inflammatix Inc.: Advisor/Consultant (Ongoing)

David C. Gaston, MD PhD: American Society of Microbiology: Honoraria (Terminated); DiaSorin: Honoraria (Terminated, September 10, 2023); Quidel: Honoraria (Terminated, October 6, 2023); T2Biosystems: Grant/Research Support (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the current state of metagenomics, unmet needs and limitations, and regulatory considerations;
identify the patient populations and clinical scenarios for which metagenomic testing would have the greatest potential clinical impact;
explain how to integrate diagnostic and stewardship efforts with metagenomic testing to enhance care.

Presentations:

1:45 PM – 2:10 PM US PT

Clinical Metagenomics: Current State & Opportunities
Speaker: Etienne Ruppe, PharmD, PhD (he/him/his) – Université Paris Cité
2:10 PM – 2:35 PM US PT

Clinical Metagenomics: Leveraging clinical impact
Speaker: Catherine Hogan, MD, MSc – British Columbia Centre for Disease Control
2:35 PM – 3:00 PM US PT

Clinical Metagenomics: Roadmap for the future
Speaker: David C. Gaston, MD PhD – Vanderbilt University Medical Center